Financing ·
Verastem raises $234.7M via underwritten offering of common stock and pre-funded warrants at $8.00 per share
VSTMVerastem, Inc.
Verastem, Inc. entered into an underwriting agreement with Jefferies LLC and Guggenheim Securities to sell 30,937,500 shares of common stock and pre-funded warrants for up to 312,503 additional shares. The securities were priced at $8.00 per share and $7.9999 per warrant, respectively. After deducting underwriting discounts and estimated offering expenses, the company expects net proceeds of approximately $234.7 million. Closing is expected on or about October 15, 2026. Verastem operates in the biotechnology industry, developing targeted therapies for cancer.